Companies › CARsgen Therapeutics
3 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CT011 CAR-GPC3 T Cells Injection Anti-GPC3 CAR-T cell therapy | GPCS | Phase 1 | HCC | Dec 2026 |
| CT041 autologous CAR T-cell injection anti-CLDN18.2 chimeric antigen receptor T-cell | CLDN18 | Phase 1 | Pancreatic Cancer; Gastric Cancer; Gastric Adenocarcinoma | Dec 2026 |
| zevor-cel (CT053) autologous CAR-T cell therapy targeting BCMA | – | Phase 1 | Multiple Myeloma | Dec 2034 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05911217 | CT041 autologous CAR T-cell injection | Phase 1 | Pancreatic Cancer | Oncology | Dec 2026 |
| NCT06560827 | CT011 CAR-GPC3 T Cells Injection | Phase 1 | HCC | Oncology | Dec 2026 |
| NCT03915184 | zevor-cel (CT053) | Phase 1 | Multiple Myeloma | Oncology | Dec 2034 |
| NCT04404595 | CT041 autologous CAR T-cell injection | Phase 1 | Gastric Cancer | Oncology | Sep 2035 |
| NCT04581473 | CT041 autologous CAR T-cell injection | Phase 1 | Gastric Adenocarcinoma | Oncology | Jun 2038 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.